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ABSTRACT 
 
The use of additive chemicals such as pesticides has become commonplace in 
agricultural practices in the Midwestern United States. Metolachlor, an herbicide used to 
regulate broadleaf weeds in corn and soybeans, is a widely utilized pesticide in the 
United States. This herbicide is effective in killing broadleaf weeds but has detrimental 
effects and consequences in non-target organisms. It is a frequent contaminant of ground 
water due to post application run-off and the air. 
Inhalation constitutes one route of exposure, in addition to ingestion, adding to the 
list of unintended targets and consequences. This route of exposure creates an argument 
for investigation into the effects of metolachlor through inhalation. There is a deficit in 
research studying the effects that metolachlor has on human health and this presents 
cause for conducting additional research. In this study, we examined the effects of 
metolachlor on alveolar monocytes and macrophages; specifically we were interested in 
determining if there were changes in several functional processes after metolachlor 
exposure. This study focused on three distinct cellular functions; phagocytosis, apoptosis 
and production of reactive oxygen species (ROS) after exposure to increasing 
concentrations of metolachlor, (50 parts per billion (ppb), 100ppb, 500ppb and 1000ppb) 
at three distinct time points, (24, 48 and 72 hours). We conducted an analysis of the 
phagocytosis and apoptosis trials by flow cytometry, while ROS we conducted an 
analysis by measuring a change in fluorescence.
 
 
Phagocytosis trials yielded no significant differences regardless of concentrations, 
time points or cell types. Apoptosis experiments yielded results that demonstrated a 
relationship between metolachlor and a change in function, for monocytes and 
macrophages during the trials. ROS measurements yielded no significant relationship 
between metolachlor exposure and production of reactive oxygen species in alveolar 
monocytes.  
 
 
 
 
 
  
 
 
THE EFFECTS OF METOLACHLOR EXPOSURE ON THP-1 ALVEOLAR 
MONOCYTE AND MACROPHAGE FUNCTION  
 
 
 
 
 
 
A Thesis  
Submitted  
In Partial Fulfillment 
Of the Requirements for the Degree 
Master of Science 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jared S. Parmater 
 
University of Northern Iowa 
 
May 2017 
ii 
 
This Study by: Jared S. Parmater 
Entitled: The effects of metolachlor exposure on THP-1 alveolar monocyte and 
macrophage function 
 
has been approved as meeting the thesis requirements for the  
Degree of Master of Science 
 
    
Date  Dr. David McClenahan, Chair, Thesis Committee 
 
 
Date  Dr. Darrell Wiens, Thesis Committee Member 
 
 
Date  Dr. Kavita Dhanwada, Thesis Committee Member 
 
 
Date  Dr. Kavita Dhanwada, Dean, Graduate College  
iii 
 
DEDICATION 
 
I dedicate this document to all of the teachers, professors and mentors who have guided 
me along the way. While it is arguable that every teacher made an impact over the years, 
there are those that stand above the rest. It is to these worthies that I direct my most 
sincere gratitude: Brent Patterson, Debra Vaughan, Dr. Theresa Spradling, Dr. Steve 
O’Kane, Mary McDade, Dr. Peter Berendzen and Dr. David McClenahan. Without your 
efforts, this document and much of my success would not have been possible. My best 
regards. Most especially, I would also like dedicate this document to my loving wife 
Jessica Parmater and my daughter Fiona Mae Parmater, who have been perhaps the 
greatest teachers of all.  
  
iv 
 
ACKNOWLEDGEMENTS 
 
I would like to thank the members of my committee, Dr. Darrell Wiens, Dr. Kavita 
Dhanwada and most especially, Dr. David McClenahan for taking the time to review my 
efforts and provide the direction necessary to produce my best work. I would also like to 
thank Max Su for his work completing the ROS portion of this study. Lastly, I would like 
to thank the University of Northern Iowa, the Graduate College and most especially the 
Department of Biology.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
TABLE OF CONTENTS 
      
                                         PAGE 
LIST OF FIGURES .......................................................................................................... vii 
CHAPTER 1: INTRODUCTION ........................................................................................1 
CHAPTER 2: METHODS .................................................................................................12 
 Experimental Design ....................................................................................................12 
 Cells and Media ...........................................................................................................12 
Metolachlor Quantification ..........................................................................................13 
Phagocytosis ................................................................................................................14 
Apoptosis .....................................................................................................................17 
Reactive Oxygen Species .............................................................................................19 
Statistical Analysis .......................................................................................................20 
CHAPTER 3: RESULTS ...................................................................................................23 
Phagocytosis Results ....................................................................................................23 
Apoptosis Results.........................................................................................................34 
Reactive Oxygen Species Results ................................................................................42 
CHAPTER 4: DISCUSSION .............................................................................................45 
Future Research ...........................................................................................................49 
REFERENCES ..................................................................................................................52 
APPENDIX A: PHAGOCYTOSIS TRIALS ....................................................................58 
APPENDIX B: APOPTOSIS TRIALS ..............................................................................66 
APPENDIX C: REACTIVE OXYGEN SPECIES ............................................................76 
APPENDIX D: ANOVA TABLES ...................................................................................78 
vi 
 
APPENDIX E: TUKEY POST-HOC ANALYSIS TABLES ...........................................87 
 
 
 
  
vii 
 
LIST OF FIGURES 
 
FIGURE                  PAGE 
1. 24 Hour Monocyte Phagocytosis Trials .................................................................24 
 
2. 48 Hour Monocyte Phagocytosis Trials .................................................................25 
 
3. 72 Hour Monocyte Phagocytosis Trials .................................................................26 
 
4. Monocyte Phagocytosis Comparison .....................................................................27 
 
5. 24 Hour Macrophage Phagocytosis Trials .............................................................29 
 
6. 48 Hour Macrophage Phagocytosis Trials .............................................................30 
 
7. 72 Hour Macrophage Phagocytosis Trials .............................................................31 
 
8. Macrophage Phagocytosis Comparison .................................................................32 
 
9. Q2 Monocyte Apoptosis Experiment Over Time ..................................................35 
 
10. Q4 Monocyte Apoptosis Experiment Over Time ..................................................36 
 
11. Q2 Macrophage Apoptosis Experiment Over Time ..............................................38 
 
12. Q4 Macrophage Apoptosis Experiment Over Time ..............................................39 
 
13. 24 Hour ROS Trials ...............................................................................................43 
 
 
 
 
1 
 
CHAPTER 1 
INTRODUCTION 
 
The use of additive chemicals such as pesticides have become commonplace in 
current agricultural practices, especially those in the Midwestern United States. 
Metolachlor is a pre-emergent broad-spectrum herbicide used to control broadleaf plants 
and weeds, primarily on agricultural or feed crops such as corn, soybeans and sorghum. It 
is also used on a myriad of plants and crops such as ornamentals, trees, shrubs, cotton and 
peanuts, but not at similar high levels. This herbicide, which inhibits protein and 
chlorophyll synthesis in targeted plant cells, is effective in killing broadleaf weeds and 
has shown to have detrimental effects and unintended consequences (Delaware 2010). 
Metolachlor was introduced to the market in 1976 (EPA 1997) but was not given its 
initial EPA Registration Standard until 1980. Established standards consisted of tests used 
to determine the toxicity and effects of a chemical compound on the environment and 
results in an environmental designation for the chemical. Depending on the designation 
the chemical receives usage can be restricted and the allowable application process can 
be determined as well as the limits of the impact, on the environment or non-target 
organisms. Presently, the EPA has a lifetime Health Advisory (HA) of 100 ppb for 
metolachlor (EPA 1997). Health Advisories are non-enforceable guidelines that provide 
information on drinking water contaminants that can cause human health effects. They 
provide guidance to local and state health agencies on technical applications, 
methodologies and treatment for drinking water contamination.  
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 Metolachlor, the scientific name ([2-chloro-N-(2-ethyl-6-methylphenyl)-N-(2-
methoxy-1-methylethyl) acetamide] is found in four isomers (R vs S), wherein 95% of 
active species are stereo isometric S (Rivard 2003). The chemical activity of metolachlor 
has important functions that affect various metabolic processes (Zhan et al. 2006). It has 
been shown to inhibit long-chain fatty acid synthesis in leek seedlings (Schmalfuβ et al. 
2000), but the unintended consequences, especially those on non-target organisms, are 
largely uncertain. It is found in various forms but is commonly encountered as an 
odorless, clear to amber colored liquid. There are twenty-one known degradates (Elias 
and Bernot 2014) and they are found in many different products on the market, alone or 
alongside other chemicals. Various trade names for metolachlor include Bicep®, CGA-
24705®, Dual®, Pennant® and Pimagram®. It is most often combined with are atrazine, 
cyanazine and fluometuron. 
In the U.S. alone, approximately 60 million pounds of metolachlor is added to 
farm fields annually. Metolachlor and its degradates have proved to be frequent 
contaminants of ground water due to post application run-off (Savoca et al. 2001). 
Ingestion via a contaminated water source remains the most likely route of exposure, 
though recent studies have pointed to metolachlor’s propensity to contaminate the air as 
well (Kurt-Karakas et al. 2011). This then, provides another route of exposure, via 
inhalation, and the possibility of another mechanism for unintended targets and 
consequences. There is currently very little with regard to regulation for many pesticides 
and thus the effects on non-target organisms, specifically humans, remain largely 
unknown. The recommended application for metolachlor and its products is spraying on 
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the ground, followed by aerial and irrigation methods (EPA R.E.D. Facts 1995). These 
methods are largely uncontrolled beyond the basic level of chemical personal protective 
equipment. There are however, some prohibited applications, metolachlor is not intended 
to for use in greenhouses nor any enclosed areas, nor is it recommended for use on peaty, 
sandy or loamy soils (EPA R.E.D. Facts 1995). Pesticides have demonstrated an 
increased mobility in these soil types when compared to clay (Kumar and Philip 2006) 
and this mobility could potentially lead to the contamination of ground water. Another 
point of concern for the usage of metolachlor is its application on fruit bearing trees or on 
grazing areas for any livestock harvested for either meat or dairy. Metolachlor usage is 
restricted for a 12-month period prior to this harvest and subsequent consumption. 
As stated earlier, the EPA gave a classification in 1980, which was later revised in 
1986. The EPA released several classifications regarding metolachlor, encompassing a 
broad spectrum of environments. The EPA assigned a soil designation of persistent to 
moderately persistent, meaning that metolachlor will largely be maintained within the soil 
on which it was applied, but it was also determined to be moderately mobile when 
compared to similar pesticides in the Lower Wisconsin River Valley (Wietersen et al. 
1992). Metolachlor is highly reserved in ground water in its chemical form as well as in 
its many degradates (Kolpin et al. 2000). It contaminated the ground water in twenty 
states. Concentrations found in these bodies of water range from .08 – 850 ppb (.078-
849.03 μg/L) (Rivard 2003). Finally, is the role that metolachlor plays in air 
contamination. It can volatize; in this state, the pesticide is able to cover great distances 
(Yao et al. 2008). Findings in watersheds in Ontario, Canada demonstrated it at 
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approximately 5ng/L (Kurt-Karakas et al. 2011) and these watersheds were several terrain 
features from the point of application. There was also a study completed in Iowa, 
specifically examining the dust contamination in Iowa homes (Curwin et al. 2005). This 
demonstrated the propensity of metolachlor to adhere to dust particles and travel 
anywhere the dust does. The study showed that ~50% of 39 homes in Iowa study had 
measurable levels of metolachlor (Curwin et al. 2005). Occupational exposure is a likely 
route to exposure, especially if the workers applying metolachlor, or working in fields in 
which metolachlor has been applied, fail to follow the guidelines for personal protective 
equipment (PPE) (EPA 1997). Exposure via inhalation is the basis of concern behind this 
study. Alongside exposure to dust contamination and subsequent inhalation, metolachlor 
is introduced to a household via exposed dust adhering to the clothing and shoes of 
individuals. 
 Metolachlor has a Toxicity Category by the EPA (EPA R.E.D. Facts 1995). It 
shows a generally low level of toxicity on acute tests, and was assigned a Toxicity 
Category III for oral and inhalation routes and a Toxicity Category IV for eyes or skin 
(EPA 1997). Subsequent animal testing has shown that chick embryos exposed to 
metolachlor resulted in an increased mortality rate when compared to control (Keseru et 
al. 2003). Another study demonstrated that pregnant rats exposed to metolachlor resulted 
in increased liver and kidney size, as well as an increase in both maternal and fetal 
toxicity (Vieira et al. 2016). Additionally, a study completed on 150 pregnant women 
(Barr et al. 2010) that found an inverse correlation between low birth weights and 
metolachlor concentrations in umbilical cords.  
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The symptoms of metolachlor poisoning are many. At high levels of exposure, a 
person can experience any of the following: eye or skin irritation, shortness of breath, 
weakness, excessive sweating and diarrhea. Furthermore, advanced symptoms include 
anemia, hypoxemia, convulsions, and jaundice (EPA 1997). Toxicity data from  long term 
rodent studies and a one year-long study (Hazelette and Arthur 1989) in which a decrease 
in the kidney weight of beagle dogs was observed was used to determine a no observed 
adverse effect level (NOAEL) of 3.5 µg/kg of body weight (WHO 1996). The NOAEL is 
the highest level of exposure at which no adverse or toxic effect is observed.  
The studies described provide a strong argument for further investigation into the 
effects of metolachlor on non-target organisms, including humans. As already stated, 
there is little research studying the potential detrimental effects of metolachlor on non-
target organisms. Thus, this study will add to the literature. We ask what the effect of 
metolachlor is when we expose human alveolar monocytes to varying levels of the 
chemical. We studied three specific cellular functions and two cell types, monocytes and 
macrophages.  
Initially, we examined the effects that metolachlor has on the phagocytic process 
of alveolar monocytes and macrophages, specifically those of the THP-1 line. THP-1 
cells are alveolar cells of a human monocytic lineage derived from a 1-year old human 
male with acute leukemia (Chanput et al. 2014). This cell line is ideal for analysis of 
protein-protein interactions and analyzing the cells via immunohistochemical techniques. 
(Chanput et al. 2014) 
6 
 
Monocytes are an important cell in immune function. These cells initially develop 
in bone marrow and subsequently enter the bloodstream. They eventually migrate to and 
enter the various tissues of the body wherein they specifically mature into macrophages. 
These macrophages are unique to the tissues in which they mature and in addition to the 
general functions of most phagocytic cells, develop processes unique to tissue in which 
they reside. In the case of THP-1 monocytes, they will mature into alveolar macrophages. 
These cells are paramount to the immune system, lauded as “sentinel cells” the first line 
of contact against foreign invaders in the body. They serve, primarily as the engine for 
phagocytosis within the lungs and play a role in inflammation, antigen processing and 
presentation and cytokine production (Chanput et al. 2014). 
Monocytes and macrophages are responsible for phagocytosis. In this process, the 
cells collect and envelop foreign material that enters the body and this engulfment helps 
to prevent infection by destroying microorganisms and materials before they have a 
chance to infect the organism’s respiratory system. Thus if the level of these cells in the 
organism is altered there could be a potential risk for respiratory infection or disease. 
Therefore, we want to determine if metolachlor exposure alters the function of 
phagocytosis in these cells (EPA 1997). Three possible outcomes could result from our 
phagocytic trials: inhibition of function, increased function or no alteration in function. If 
metolachlor inhibits or prevents phagocytosis in leukocytic cells this function would be 
carried out in a reduced capacity or the cells could perhaps lose the ability to carry out 
normal phagocytic function altogether. In this case, it is possible that there would be an 
increase in foreign bodies in the lungs and a higher risk of infection due to external 
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influences. A study conducted on leopard frogs demonstrated that pesticides have 
deleterious immunotoxic effects on an organism’s resistance to infections (Christin et al. 
2003). This study exposed juvenile frogs to a mixture of six pesticides including atrazine, 
metribuzin, aldicarb and others for 21 days. They detected no alteration to phagocytic cell 
numbers at all levels of concentration. However, when exposed to an infectious parasite, 
there was a marked decrease in phagocytic function at the highest exposure level. This 
demonstrated that though phagocytic cell levels remained constant throughout the study, 
the capacity to carry out phagocytic function was impaired at the highest level of 
exposure. These animals also presented a greater prevalence of lung infections at the 
highest level of pesticide exposure (Christin et al. 2003).  
At the opposite end of the spectrum, if metolachlor caused an increase in 
phagocytic function it could lead to increased inflammation in the lungs and even cause 
the wrongful destruction of other cells incorrectly identified as foreign bodies. This could 
also result in increased infection in the organism’s respiratory system as it essentially 
damages itself. A recent study examining neutrophils concluded that uncontrolled 
phagocytosis and release of oxidative compounds in extracellular space could damage 
surrounding tissues (Moraes et al. 2006).  Finally, metolachlor may simply not have any 
relevant effect on phagocytic function.    
The second portion of this study examined the effect of metolachlor on apoptosis, 
the process of highly regulated cellular death. Estimates suggest that between 50 and 70 
billion cells die every day in an adult human body (Bianconi and Piovesan 2013). The 
process of apoptosis promotes normal biological development, homeostasis and runs 
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counterpoint to cell proliferation. It serves as a maintenance process and can remove any 
unwanted or damaged cells, such as those that may become cancerous (Bianconi and 
Piovesan 2013). 
The process of apoptosis is complex and there are several ways in which a cell is 
triggered to undergo this process. One crucial molecule involved in this process is 
phosphatidylserine. Phosphatidylserine is an important phospholipid found in most cells. 
It is oriented towards the cytosolic side of cellular membrane and used to detect the 
initiation of apoptosis. Phosphatidylserine acts upon by flippase, an enzyme that 
translocates phospholipids, upon the initiation of apoptosis and it assumes a reverse 
orientation (Hankins et al. 2015). This orientation signals macrophages for destruction 
and provides pathways for the removal of damaged or unhealthy cells (Hankins et al. 
2015). This is a completely normal and extremely critical function within cells and it 
serves to maintain homeostasis in tissues. In this study, we were primarily interested in 
the process of apoptosis but we examined if necrosis also occurred in the sample cells. 
Necrosis is the process of premature cell death and is caused by outside factors such as 
severe mechanical damage, toxins or infections. It can cause an inflammatory response 
that can block normal phagocytic function and can spread, causing damage to 
surrounding tissues. Very simply put, it is traumatic cellular death and can be catastrophic 
for an organism. A recent study (Caviello et al. 2006) has shown that pesticides can have 
damaging proapoptotic effects on Wistar rat fibroblasts in culture as well as peripheral 
blood mononucleated cells (PBMC) after exposure to the fungicide Mancozeb. At the 4 
hour, treatment indicated that it induced apoptosis in both fibroblast and PBMCs 
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(Caviello et al. 2006). This same study also determined that with exposure to higher 
concentrations of Mancozeb or when exposed for the longer exposure periods, post-
apoptotic and necrotic alterations in cell membrane integrity were identified (Caviello et 
al. 2006). Thus, pesticides have a demonstrated association with cellular apoptosis.  
As in phagocytosis, there were three possibilities that could arise from exposure; 
an inhibition of function, an increase in function or no measurable change. However, if 
cell death was not occurring by apoptosis, there was also the possibility of necrosis. If 
metolachlor exposure inhibited apoptotic function, cells would not undergo the critical 
task of general cellular housekeeping, possibly resulting in the perpetuation of damaged, 
unhealthy cells. In a study conducted regarding the development of ocular lesions in rats, 
when exposed to organophosphate-based insecticide in vivo, researchers were able to 
demonstrate that levels of apoptosis increased in the test samples, especially in the 
subjects that developed lesions (Fu et al. 2008). This potential for an increase in 
apoptosis, healthy cells carrying out normal functions would be no longer present to carry 
out their function, in this instance the process of phagocytosis. A study examining the 
effect of organophosphorous pesticides on apoptosis in natural killer cells (NK) 
suggested that pesticide exposure partially mediated the loss of NK function (Qing et al. 
2007). This then, could potentially lead to further infection in the respiratory system as 
the monocytes and macrophages responsible for attacking and destroying foreign bodies 
and materials would no longer present or would be present in a diminished degree. A 
recent study examined this relationship in mice infected with the influenza virus and 
subsequently introducing Streptococcus pneumoniae (Ghoneim et al. 2013). Nearly 90% 
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alveolar macrophages had been lost at one-week post influenza infection. The researchers 
found that macrophage mediated bacterial clearance was severely reduced in the 
influenza impaired mice with approximately 50% less bacterial inoculum having been 
cleared when compared to the control. There also remained the possibility that 
metolachlor exposure might not have any effect on apoptosis at all. Finally, it was 
possible that metolachlor could cause necrosis in these cells, increasing the likelihood of 
uncontrolled and aberrant death, possibly causing an increase in respiratory infection or 
other complications.  
The third function that we examined in this study was the production of reactive 
oxygen species. ROS are a crucial weapon in the arsenal of monocytes and macrophages. 
ROS generated in immune cells, are part of the killing pathway of macrophages (Liew 
and Millot 1990). ROS serve as a chemical weapon for leukocytes during phagocytosis, 
to damage invaders (Meir and Hertzel 2002). These products are critical in the function 
of phagocytosis in that they are the chemical weapons that immune cells use to degrade 
foreign microbes and materials. However, these chemicals and this process can get out of 
control and can damage an organism’s own cells (Meir and Hertzel 2002). NADPH 
(nicotinamide adenine dinucleotide phosphate) is an anabolic cofactor and reducing agent 
(DeLeo 1996) that protects the organism’s cells against ROS via redox and serves to 
assist in regulation of these chemicals. If we interfere with this agent, it is possible that 
there could be a reduction in the regulation of the various ROS present in these cells. A 
recent study looked at the effects of pesticide exposure on the immune system of juvenile 
trout (Shelley et al. 2009). The researchers noted an increase in phagocytic cells and 
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observed that at the 28-day exposure there was an elevated presence of respiratory burst, 
a function of ROS (Shelley et al. 2009).  
ROS in excess can be damaging to the body’s lipids, proteins, and DNA thus, it is 
important to determine what, if any, effects of metolachlor there may be ROS production 
in THP-1 cells. In this portion of the study, we sought to examine the effects that 
metolachlor exposure had on the production of these chemicals and understand whether it 
inhibits production, increases production or has any effect at all. If metolachlor inhibits 
production of these chemicals the cells that use them to carryout phagocytosis could have 
a decreased function or lose the function altogether. Conversely, if metolachlor increased 
the production of these volatile chemicals, these cells could create an inhospitable 
environment within the organism’s respiratory system, potentially destroying other cells 
within the body. A study conducted on dystrophin deficient mice demonstrated that there 
was an increase in oxidase activity in the hearts of these mice and that this increased 
activity was a likely contributor to heart failure (Williams and Allen 2007). Metolachlor 
could also have no measurable effect on this function and yield no measurable changes to 
these processes.  
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CHAPTER 2 
METHODS 
Experimental Design 
In order to determine the effects of metolachlor across the cellular functions of 
interest with the two cell types used, it was important that we design a small, detailed 
series of protocols utilizing assays particular to each function. The three functions that we 
analyzed were phagocytosis in monocytes and macrophages, apoptosis and necrosis in 
both monocytes and macrophages, and the production of reactive oxygen species in 
monocytes. 
Cells and Media 
The cells utilized for during this study were THP-1 cells, a human monocytic cell 
lineage derived from a 1-year old human male with acute leukemia (ATCC). Medium 
was prepared as complete growth medium in RPMI (ATCC), 20% fetal bovine serum 
(FBS) and 0.4% 2-β mercaptoethanol. We maintained cells in a 37.0° C with 5% CO2. 
We maintained cell cultures by the addition of fresh medium to the culture flask every 2-
3 days. Cells were counted by staining 5 μl of the cell culture with 5 μl Trypan blue stain. 
We pipetted stained cells onto a cell plate and estimated cell numbers were determined 
with a cell-reading device. We performed cell counts using a hemocytometer and 
counting cells with an inverted microscope. We monitored cell counts to ensure that the 
culture did not exceed 1x10ˆ6 cells/ml of culture. As we used cells, few added fresh 
medium to bring the culture levels up to approximately 10-12 mL. When preparing an 
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experiment, we took cells counts, and when cell numbers were ~1x10ˆ6 cells, pipetted 
cells into the well plates for treatment and study in accordance with experimental design.  
Metolachlor Quantification 
We conducted metolachlor quantification so that the concentration of metolachlor 
could be determined and controlled for further experimental application. In keeping with 
the quantification protocol, a small concentration of stock metolachlor, we added 
approximately 1 mg/µl, to 100ml of complete medium. We then placed metolachlor 
medium in a light-protected bottle, we added approximately 5 µl of this solution to a test 
vial and the metolachlor medium was refrigerated.  
Approximately 5 µl of the metolachlor stock was added to a flask with 50 ml of 
acetonitrile. This flask was marked as 100 ppm and utilized in the preparation of all 
subsequent dilutions. The dilution flasks were prepared with acetonitrile and decreasing 
amounts from the 100 ppm metolachlor sample flask in keeping with protocol and the 8 
dilutions ranged between 100 ppm and 5 ppm. Approximately 5 µl of each dilution 
sample was added to a pre-marked sample vial and the samples, including the 
metolachlor medium sample and were placed on ice. We then took these samples to an 
HPLC (Agilent) and a mass spectrum analysis and conducted for each sample. We did 
this to generate a standard concentration curve for sample comparison. Designated 
metolachlor samples served as a basis for the comparison and determination of the 
metolachlor concentration. We used this concentration in calculations for metolachlor 
exposures.  
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Phagocytosis 
For the phagocytic study, we used a phagocytosis assay kit and the provided 
protocol (Cayman Chemical). We cultured cells in in 10-12 mL of complete medium in 
standard culture flasks. We exposed THP-1 (~1x10ˆ6) to varying amounts of metolachlor: 
0, the control, 50, 100, 500 and 1000 ppb, for 24, 48 or 72 hours. 
We maintained cells at 37° C with 5.0% CO. After 24, 48 or 72 hours of 
exposure, we exposed THP cells to 200 μl of fluorescently labeled, rabbit IgG coated 
latex beads. These beads are recognized as a foreign molecule by the THP-1 cells and are 
phagocytized by them. After exposure to the beads for 24 hours, we washed samples 
multiple times with sterile PBS to remove excess beads that were not phagocytized, 
centrifuged at 8000 rpm for 5 minutes, suspended in assay buffer, centrifuged at 8000 
rpm for an additional 5 minutes and re-suspended in assay buffer at a volume of 500 μl.  
We analyzed the prepared samples by flow cytometry using the Attune Acoustic 
Focusing Cytometer (Applied Biosystems). Essential to appreciating the data generated 
by this step is basic understanding of the function of flow cytometry. Flow cytometry is, 
in essence, the measurement of the characteristics of single cells suspended in a saline 
stream that is funneled past a laser. It is the measurements taken after the laser is passed 
through the cell that allows for the characterization of the cell size, granularity and most 
importantly for this study, anything that the cell might contain within it. As stated 
previously, the latex beads from the assay kit, coated with a fluorescent tag that is excited 
when a laser strikes it. This fluorescent tag absorbs the light from the laser and emits a 
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flash of light that can be read by the sensors in the flow cytometer. This difference 
between absorbed light and emitted light is known as a Stokes Shift. This emission 
allows for the characterization of the cell and demonstrates if the cells were able to carry 
out phagocytic function. The intensity of the fluorescent emission by an individual cell is 
proportional to the amount of beads phagocytized, therefore, the amount of fluorescence 
of treated cells compared to the control will allow for the determination of a change in 
phagocytic function.     
A benefit of this method is that it allows us to measure each cell individually 
within the sample. These readings can then be plotted on a scatter plot and gates assigned 
to include approximately 80% of the total samples taken.  
For the phagocytosis trials, we conducted our analysis using flow cytometry. 
Three different displays were used: FSC + SSC (forward scatter and side scatter), FSC+ 
BL1 (forward scatter and green filter 1) and a histogram demonstrating BL1 (green filter 
1). For each experiment, displays and the gates were set based upon the control sample 
findings and the settings saved. An analytical gate was set around the points of no less 
than 80% of the total body of data points. These data were compared among the 
concentrations (i.e. control, 50, 100, 500 and 1000 ppb) within the time points of 24, 48 
and 72-hrs. The amount of fluorescence of treated cells compared to the control allowed 
for the determination of a change in phagocytic function. For the monocyte phagocytosis, 
8 individual experiments were conducted with one replicate for each concentration at 
each time point, at 24, 48 and 72-hours.  
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The macrophage phagocytosis experiment was nearly identical to the monocyte 
trials, with similar metolachlor concentrations as well as times. In order to differentiate 
the immature monocytes into their differentiated counterpart, we added Phorbol 
Myristate Acetate (PMA). PMA is a substance that stimulates cellular activation as well 
as differentiation and stimulates cell proliferation (Rutherford et al. 1993). We used it in 
this case, to transform our monocytes into macrophages. Exposure to 4 µg/ml PMA 
occurred 24 hours prior to the cells being treated with the latex beads. The protocol then 
proceeded in an identical fashion to that of the monocyte experiment. For the macrophage 
phagocytosis, 5 individual experiments with one replicate per sample were completed for 
all times at 24, 48 and 72 hours.   
 
 
 
 
 
 
 
 
 
17 
 
   Apoptosis  
We cultured cells in complete cell culture medium. In this experiment, THP-1 
(~1x10ˆ6) cells were exposed to varying amounts of metolachlor: 0, or control, 50, 100, 
500 and 1000 ppb for 24, 48 or 72 hours. We maintained cells at 37° C with 5.0% CO ₂. 
For this experiment, we utilized The Dead Cell/Apoptosis kit with Alexa Fluor and 
Propidium Iodide (Molecular Biosystems).  
The assay exploited the presence of phosphatidylserine (PS), a phospholipid, 
which is present in the outer leaflet of the cell membrane of THP-1 cells undergoing 
apoptosis. Annexin-V stain, which when conjugated to a fluorochrome, binds to the 
available and exposed PS in the cell membrane. When this substance binds to PS, it will 
fluoresce when excited by a laser and is measured via flow cytometry.  
Propidium iodide (PI) binds to nucleic acids. In order to see a signal for PI, the 
cell membrane needs to be damaged and leaky (Marchetti et al. 1996) to allow PI to 
move inside of the cell. This altered permeability can be an indicator of either necrosis 
(lethal damage) or possibly late stage apoptosis (extremely porous membrane). PI can 
also be detected via fluorescence when exposed to the laser in the flow cytometer. We 
added the two stains, Annexin-V and PI to control and metolachlor-treated cells and 
incubated for 15 minutes in the darkness. We then washed the cells to remove excess 
stain and PI, centrifuged at 8000 rpm for 5 minutes and suspended in assay buffer. We 
placed the samples on ice and subjected to the flow cytometer analysis for 
characterization and quantification.    
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We completed an n analysis of apoptosis and necrosis using flow cytometry. The 
display was designed to provide four different data points. FSC + SSC (forward scatter 
and side scatter), FSC+ BL1 (forward scatter and green filter 1), BL1 + BL3 (green filter 
1 and red filter 3) and a scatter plot demonstrating BL1 + BL3 (green filter 1 and red 
filter 3). We decided on a blue laser (495λ), as it was able to provide the wavelength 
necessary to excite the Annexin V protein and the PI molecule (Alexa Fluor®). These 
signals were critical in establishing the differences in cells undergoing apoptosis and 
those undergoing necrosis (Alexa Fluor®).  
Each experiment began with the experimental controls and displays and we 
divided the output into quadrants. We based the quadrants upon the data from the control 
trials. Approximately 80% of the total points were placed within quadrant 3 (Q3) and the 
workplace was then saved. The quartiles divided the experimental field into four distinct 
fields; quadrant 1 (Q1) were cells undergoing necrotic activity (high PI stain, low 
Annexin V stain), quadrant 2 (Q2) were cells undergoing late stage apoptosis(high PI 
stain, high Annexin V stain), quadrant 3 (Q3) were considered to be cells not undergoing 
apoptosis nor necrosis (low PI and low Annexin V) and quadrant 4 (Q4) were cells 
considered to be undergoing apoptosis (low PI and high Annexin V stain). Data for each 
trial was recorded and the output of the four quadrants was utilized to derive the statistics 
for analysis. We used change in quartile percentages to determine alteration in cellular 
function in this experiment. For the macrophage, experiment monocytes were exposed to 
4 µg/ml PMA to differentiate control and treated cells for 24 hours to transform the 
monocytes into macrophages. For the monocyte apoptosis, there were 5 individual 
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experiments and for macrophage apoptosis, 4 individual experiments were performed. 
There was at least one replicate for each of the samples in each experiment for all of the 
time points; 24, 48 and 72 hours.  
  Reactive Oxygen Species  
To determine the effects of metolachlor on the production of reactive oxygen 
species in THP-1 monocytes we performed an assay to measure the level of these 
compounds. We maintained cells in complete medium at 37° C with 5.0% CO ₂. 
Approximately (~1x10ˆ6) cells were used in each experiment. We exposed cells to 
varying concentrations of metolachlor: 0, 50, 100, 500 and 1,000 ppb along with a 
positive and negative control for 24-hours. Yutao (Max) Su, a student during Aug`13-
Aug`14 term, completed this work and the statistical analysis is the only portion that I 
completed.   
Cells, treated and control, were exposed to a substrate (florigenic peroxidase 
substrates) thirty minutes prior to reading the cell plate to quantify live cell fluorescence. 
Florigenic peroxidase substrates became highly fluorescent upon exposure to H₂O₂ and 
fluorescence detected via a fluorescent plate reader. The fluorescence will increase or 
decrease depending on the level of H₂O₂ in cell. If there is an increase in fluorescence, 
there is an increase in H₂O₂ within the sample. Conversely, if there is less fluorescence 
present in the sample, then there is less H₂O₂ present. We used a spectrophotometer to 
quantify fluorescence and count the events per sample. We compared the amount of 
fluorescence of treated cells to the level of fluorescence in control cell to determine if 
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there is an effect of varying levels of metolachlor on THP-1 cells. For this ROS assay, we 
conducted six individual experiments using monocytes for each concentration at 24-
hours. We completed at least one replicate for the vehicle control and at each 
concentration for all six experiments.  
Statistical Analysis 
For the monocyte and macrophage phagocytosis experiments, the statistical mean 
was taken from each of the data points and data was normalized within each sample, 
providing the basis for further in-depth analysis. A comparison using ANOVA was 
performed in an effort to determine the significance of the data at α=0.05. The null was 
set as follows. Null Hypothesis: metolachlor treatments will have no effect on phagocytic 
function in THP-1 monocytes. We used metolachlor treatments as the random factor and 
used time point as a fixed factor. We generated an ANOVA table via R and we utilized 
the subsequent p-value in determining the significance of samples. The ANOVA table for 
the monocytic phagocytosis experiments are located in Appendix C: ANOVA Tables. For 
the monocyte phagocytosis, eight individual experiments with one sample per treatment 
or control were analyzed. 
We designed the macrophage phagocytosis experiments in the same way to the 
monocytic trials, insofar as the analysis is concerned. We normalized the sample 
statistical means were normalized and used in conjunction with an ANOVA. The α=0.05 
was set and the null was set as follows. Null Hypothesis: metolachlor treatments will 
have no effect on phagocytic function in THP-1 macrophages. An ANOVA table, 
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generated via R and the subsequent p-value was utilized in determining the significance 
of samples. The ANOVA table for the monocytic phagocytosis experiments are located 
in Appendix C: ANOVA Tables. Any results that were within the threshold of 
significance were subjected to a Tukey post-hoc for additional analysis. With 
macrophage phagocytosis, we performed five individual experiments with one replicate 
per treatment.  
The apoptosis experiments were conducted utilizing changes in quartile 
percentages for Q2 and Q4 for statistical analysis. For this experiment, Q2 and Q4 
represent distinct cell groupings within the population. The Q4 captures the fluorescent 
signature of cells that have conjugated with the Annexin-V stain are undergoing 
apoptosis. The Q2 is representative of a fluorescent signature that is a combination of the 
Annexin-V emission as well as that of propidium iodide. This blended signature is 
indicative of both necrosis and late-stage apoptosis. The difference between these two 
states is that in late-stage apoptosis cellular membranes are very porous and can allow for 
the entrance of PI and subsequent binding to nucleic acids. We completed this analysis to 
examine the distribution of the data among the quartiles and movement among the 
quartiles demonstrated alterations in apoptotic function. In an effort to capture the data in 
the two quadrants in question, Q2 and Q4, this percentage was a better measure of 
change. An ANOVA was utilized to compare significance between quartile data and time 
points and α was set at α=0.05. Again, we used a Tukey post-hoc analysis whenever there 
was a significant result. The null was set as follows. Null Hypothesis: metolachlor 
treatments will have no effect on apoptotic function in THP-1 monocytes. There were five 
22 
 
individual experiments with on replicate for each sample. This entire method was utilized 
to conduct the apoptosis analysis on the THP-1 macrophages as well where four 
individual experiments were performed with one replicate for each sample. The α was set 
at α=0.05 and the null was set as follows. Null Hypothesis: metolachlor treatments will 
have no effect on apoptotic function in THP-1 macrophages. 
The third function, production of ROS (reactive oxygen species) was analyzed by 
measuring fluorescence and data recorded via the fluorescent spectrophotometer. We 
utilized this data to generate a statistical mean and then compared to the various plate 
reader outputs. This then, allowed data to be subjected to an ANOVA with α being set at 
α=0.05. The null for this experiment was as follows. Null Hypothesis: metolachlor will 
have no effect on the production of reactive oxygen species in THP-1 monocytes. We 
performed six individual experiments with one replicate per sample. There was no ROS 
experiment conducted with THP-1 macrophages due to time constraints.  
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CHAPTER 3  
 
RESULTS 
 
Phagocytosis Results 
 Results from the monocytic phagocytosis experiment yielded no 
significant difference between the control sample and the metolachlor exposures of 50, 
100, 500 and 1,000 ppb. This pattern was similar across all three time points. The mean 
of each trial was normalized (divided by the control) for each metolachlor exposure 
amount within its specific time point to reduce spread due to inconsistency and all error 
bars were generated using standard error. The 24 hour trial (n=8) yielded normalized 
means as follows (Figure 1). 
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Figure 1: Phagocytosis activity of THP-1 monocyte cells treated 24 hours with 
metolachlor. We exposed THP-1 cells to vehicle control or 50, 100, 500 or 1000 
ppb of metolachlor for 24 hours prior to the addition of fluorescent beads and 
subsequent analysis with a flow cytometer. Fold change in the goups was 
calculated by comparing each treatment group with the vehicle control. Results 
are the means ± SE of 8 replicates.  
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The 48 hour trial (n=8) yielded normalized means as follows (Figure 2).  
 
 
Figure 2: Phagocytosis activity of THP-1 monocyte cells treated 48 hours with 
metolachlor. We exposed THP-1 cells to vehicle control or 50, 100, 500 or 1000 
ppb of metolachlor for 48 hours prior to the addition of fluorescent beads and 
subsequent analysis with a flow cytometer. Fold change in the goups was 
calculated by comparing each treatment group with the vehicle control. Results 
are the means ± SE of 8 replicates.  
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The 72 hour trials (n=8) yielded normalized means as follows, see (Figure 3).  
 
Figure 3: Phagocytosis activity of THP-1 monocyte cells treated 72 hours with 
metolachlor. We exposed THP-1 cells to vehicle control or 50, 100, 500 or 1000 
ppb of metolachlor for 48 hours prior to the addition of fluorescent beads and 
subsequent analysis with a flow cytometer. Fold change in the goups was 
calculated by comparing each treatment group with the vehicle control. Results 
are the means ± SE of 8 replicates.  
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Following the completion of the monocyte phagocytosis experiment the data was 
combined to demonstrate the similarities and differences between them. The graphic 
comparison follows below (see Figure 4). 
 
Figure 4: Comparison of phagocytic activity of THP-1 monocyte cells treated 24, 
48 and 72 hours with metolachlor. Fold change in the goups was calculated by 
comparing each treatment group with the vehicle control. Results are the means ± 
SE of 8 replicates.  
 
The relevant data sets are located in Appendix B: Monocyte & Macrophage 
Phagocytosis Trials. A statistical analysis of the normalized means was conducted as per 
an ANOVA set α =0.05.  Null hypothesis: metolachlor treatments will have no effect on 
phagocytic function in THP-1 monocytes. 
The outcome of the ANOVA for the monocytic phagocytosis trials provide for a 
p-value of 0.932. This statistic when paired with α=0.05 demonstrates no likely 
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significance (see Appendix C: ANOVA Tables).  Due to the probability that this 
difference is very low, we fail to reject the null hypothesis. This failure to reject the null 
hypothesis demonstrates that with a 95% certainty, metolachlor had no significant effect 
on the phagocytic function of THP-1 monocytes. 
Results from the macrophage phagocytosis experiment yielded no statistical 
difference between the control sample and the metolachlor exposure samples (50, 100, 
500 and 1,000 ppb). This finding was consistent across all three time points, 24, 48 and 
72 hours. We normalized the mean of each sample by dividing it by the sample control 
within its specific time trial to reduce spread due to inconsistency. The 24 hour trials 
(n=4) yielded normalized means as follows (Figure 5).  
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Figure 5: Phagocytosis activity of THP-1 macrophage cells treated 24 hours with 
metolachlor. We exposed THP-1 cells to vehicle control or 50, 100, 500 or 1000 
ppb of metolachlor for 24 hours prior to the addition of fluorescent beads and 
subsequent analysis with a flow cytometer. Fold change in the groups was 
calculated by comparing each treatment group with the vehicle control. Results 
are the means ± SE of 4 replicates.  
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The 48-hour trials yielded normalized means as follows (see Figure 6).  
 
 
Figure 6: Phagocytosis activity of THP-1 macrophage cells treated 48 hours with 
metolachlor. We exposed THP-1 cells vehicle control or 50, 100, 500 or 1000 ppb 
of metolachlorfor 24 hours prior to the addition of fluorescent beads and 
subsequent analysis with a flow cytometer. Fold change in the goups was 
calculated by comparing each treatment group with the vehicle control. Results 
are the means ± SE of 5 replicates  
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The 72-hour trials yielded normalized means as follows (see Figure 7).  
 
 
Figure 7: Phagocytosis activity of THP-1 macrophage cells treated 72 hours with 
metolachlor. We exposed THP-1 cells to vehicle control or 50, 100, 500 or 1000 
ppb of metolachlor for 48 hours prior to the addition of fluorescent beads and 
subsequent analysis with a flow cytometer. Fold change in the goups was 
calculated by comparing each treatment group with the vehicle control. Results 
are the means ± SE of 5 replicates.  
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Following the completion of the macrophage phagocytosis experiment the data 
was combined to demonstrate the similarities and differences among the trials. The 
graphic comparison follows below (see Figure 8).  
 
Figure 8: Comparison of phagocytic activity of THP-1 macrophage cells treated 
24, 48 and 72 hours with metolachlor. Fold change in the goups was calculated by 
comparing each treatment group with the vehicle control. Results are the means ± 
SE of 5 replicates..  
 
We conducted a statistical analysis utilizing the normalized means in accordance 
with ANOVA. As per the protocol, we set α = 0.05.  Null hypothesis: metolachlor 
treatments will have no effect on phagocytic function in THP-1 macrophages. The 
outcome of the ANOVA for the macrophage phagocytosis trials provided for a p-value of 
0.983657. This statistic when paired with α=0.05 demonstrates that no significance is 
likely (see Appendix C: ANOVA Tables). Due to the likelihood that there is no 
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difference between these trials, we fail to reject the null hypothesis. This failure to reject 
the null hypothesis demonstrates to 95% probability that metolachlor had no significant 
effect on the phagocytic function of THP-1 macrophages.  
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Apoptosis Results 
 Results from the monocytic apoptosis experiment yielded some noticeable 
difference between the control sample and the metolachlor exposure samples during the 
48-hour time point, specifically in Q2. The 24 and 72-hour time points did not 
demonstrate any statistical change in function in either Q2 or Q4. We utilized the 
percentage of change for each trial for this determination. The data for the graphs was 
normalized for each metolachlor exposure amount within its specific time trial to reduce 
spread due to inconsistency and error bars were generated using standard error (see 
figures 9 and 10 for Monocyte Apoptosis Q2 and Q4). 
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Figure 9: Apoptosis activity of THP-1 monocyte cells treated 24, 48 and 72 hours with 
metolachlor. We exposed THP-1 cells to vehicle control or 50, 100, 500 or 1000 ppb of 
metolachlor for the designated hours prior to the addition of Annexin V and propidium 
iodide stain  analysis with a flow cytometer. Fold change in the goups was calculated by 
comparing each treatment group with the vehicle control. These results are within the Q2 
quadrant. Results are the means ± SE of 5 replicates. * Significant (P<0.05) change when 
compared to the vehicle control. ** Significant (P<0.01) change when compared to the 
vehicle control.  
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Figure 10: Apoptosis activity of THP-1 monocyte cells treated 24, 48 and 72 hours with 
metolachlor. We exposed THP-1 cells to vehicle control or 50, 100, 500 or 1000 ppb of 
metolachlor for the designated hours prior to the addition of Annexin V and propidium 
iodide stain  analysis with a flow cytometer. Fold change in the goups was calculated by 
comparing each treatment group with the vehicle control. These results are within the Q4 
quadrant. Results are the means ± SE of 5 replicates.  
 
We conducted a statistical analysis in accordance with ANOVA for each of the 
time trials and Q2 and Q4 data. This means that the 24, 48 and 72-hour trials each had 
their own analysis of variance examining the percent change within the relevant quartiles 
Q2 and Q4. As per the protocol we set α = 0.05.  Null hypothesis: metolachlor treatments 
will have no effect on apoptotic function in THP-1 monocytes. 
The outcome of the ANOVA for the monocyte apoptosis trials provided for p-
values following: 24 hours Q2 p-value of 0.079 and Q4 p-value of 0.402, 48 hours Q2 p-
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0.204. When paired with an α=0.05 the percent change for Q2 and Q4 for the 24 hour and 
72 hour time points demonstrate that is unlikely that there is difference among these 
trials. However, the 48 hour time point showed a statistically significant difference in that 
the p-value for 48 hour Q2 is 0.002, a p-value smaller than the designated α = 0.05. This 
shift demonstrated a change in apoptosis at this time point. A Tukey post-hoc analysis 
was completed to determine the significant treatments for this time point (see Appendix 
E: Tukey Post-Hoc Analysis). Results of the analysis indicated that the 500 ppb treatment 
was significant with a 95% probability. We found that the 1000 ppb treatment was 
significant within a 99% probability. The 48-hour Q4 percent change did not meet the 
criteria for statistical significance, but it was by a very minute margin, p-value of 0.059 
(see Appendix C: ANOVA Tables). Due to the 48-hour Q2 relationship, we were able to 
reject the null hypothesis. This rejection of the null demonstrates that metolachlor had a 
significant effect on the apoptotic function of THP-1 monocytes, specifically at the 48 
hour time point and within the Q2 (late stage apoptosis) region. Upon examination of the 
data and the Q2 monocyte apoptosis graph, we can see that this alteration in function is 
an increase in apoptosis. 
Results from the macrophage apoptosis experiment yielded noticeable and 
significant difference between the control sample and the metolachlor exposure samples 
during all time points, though not all quartiles. The 24 and 72-hour time points 
demonstrated statistical change in function in Q2 and the 48-hour time point did so as 
well in Q4. We utilized the percent in change among the data of each trial for this 
determination. We normalized the data for the graphs for each metolachlor exposure 
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amount within its specific time trial to reduce spread due to inconsistency and error bars 
were generated using standard error (see figures 11 and 12 for Macrophage Apoptosis Q2 
and Q4). 
 
 
Figure 11: Apoptosis activity of THP-1 macrophage cells treated 24, 48 and 72 hours 
with metolachlor. We exposed THP-1 cells to vehicle control or 50, 100, 500 or 1000 ppb 
of metolachlor for the designated hours prior to the addition of Annexin V and propidium 
iodide stain  analysis with a flow cytometer. Fold change in the goups was calculated by 
comparing each treatment group with the vehicle control. These results are within the Q2 
quadrant. Results are the means ± SE of 4 replicates. * Significant (P<0.01) change when 
compared to the vehicle control. 
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Figure 12: Apoptosis activity of THP-1 macrophage cells treated 24, 48 and 72 hours 
with metolachlor. We exposed THP-1 cells to vehicle control or 50, 100, 500 or 1000 ppb 
of metolachlor for the designated hours prior to the addition of Annexin V and propidium 
iodide stain  analysis with a flow cytometer. Fold change in the goups was calculated by 
comparing each treatment group with the vehicle control. These results are within the Q2 
quadrant. Results are the means ± SE of 4 replicates. * Significant (P<0.01) change when 
compared to the vehicle control. 
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We conducted a statistical analysis in accordance with ANOVA for each of the 
time trials and Q2 and Q4 data. This means that the 24, 48 and 72-hour trials each had 
their own analysis of variance examining the percent change within the relevant quartiles 
Q2 and Q4. As per the protocol we set α = 0.05.  Null hypothesis: metolachlor treatments 
will have no effect on apoptotic function in THP-1 monocytes. 
The outcome of the ANOVA for the macrophage apoptosis trials provided for the 
following p-values: 24 hours Q2 p-value of 0.042 and Q4 p-value of 0.136, 48 hours Q2 
p-value of 0.301, Q4 p-value of 0.006, and 72 hours Q2 p-value of 0.007 and Q4 p-value 
of 0.102. When paired with an α=0.05 the percent change for Q2 for the 48 hour time 
point showed no statistically significant change and Q4 for the 24 hour and 72 hour time 
points demonstrate that is unlikely that there is difference among these trials. However, 
the 48-hour time point showed a statistically significant difference. The p-value for 48 
hour Q4 is 0.006, a p-value smaller than the designated α of 0.05. We completed a Tukey 
post-hoc analysis to determine the significant treatments for this time point (see 
Appendix E: Tukey Post-Hoc Analysis). Results of the analysis indicated that there was a 
significant difference between the control and the 1000 ppb treatment that was within a 
99% probability and that there was 95% likelihood that there was a significant difference 
between the control and the 100 ppb treatment. This shift demonstrated a high probability 
of change in apoptosis at this time point. In addition, the Q2 region for the 24 and 72-
hour time points yielded significant results. These respective time points had p-values 
smaller than the designated α, 24-hour p-value of 0.042 and 72-hour p-value of 0.007. 
These shifts indicated a likelihood of significant change at both of these time points and 
41 
 
the Q2 region (see Appendix C: ANOVA Tables). Due to these outputs, we performed a 
Tukey post-hoc analysis for each time point. The results of the post-hoc analysis 
indicated that there was no significant difference between the treatments for the 24-hour 
time point, but indicated that there was significance difference between several 
treatments at the 72-hour time point. Specifically, t we found that the 100 ppb treatment 
was significantly different to within a 99% probability.  
Due to the 24 and 72-hour Q2 findings as well as the 48-hour Q4 relationship we 
reject the null hypothesis. This rejection of the null demonstrates that metolachlor had a 
significant effect on the apoptotic function of THP-1 macrophages, specifically at the 24 
and 72 hour time points within the Q2 (late stage apoptosis) region and also the 48 hour 
time point and within the Q4 (apoptosis) region. Upon examination of the data and the 
Q2 and Q4 macrophage apoptosis graphs, we can see that this alteration in function is a 
decrease in apoptosis for the 24 hour and 48 hour time points, though this change was in 
different quartiles it is still representative of an alteration of apoptotic function over all. 
For the 72-hour, time point there is a marked increase in apoptosis.  
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Reactive Oxygen Species 
The last experiment completed was regarding the effects of metolachlor on the 
production of ROS within THP-1 monocytes. Results from the monocytic ROS 
experiment yielded little noticeable difference between the control sample and the 
metolachlor exposure samples 50, 100, 500 and 1,000 ppb. We only conducted this 
experiment for the 24-hour time point and yielded normalized means. The mean of each 
trial was normalized for each metolachlor exposure amount within the time trial to reduce 
spread due to inconsistency and standard error was used to produce error bars (see figure 
13). 
 We conducted a statistical analysis of the normalized mean in accordance with 
ANOVA for the 24-hour time trials. As per the protocol we set α = 0.05.  Null 
hypothesis: metolachlor treatments will have no effect on ROS in THP-1 monocytes.    
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Figure 13: ROS activity of THP-1 monocytes treated 24 hours with metolachlor. 
We exposed THP-1 cells to vehicle control or 50, 100, 500 or 1000 ppb of 
metolachlor for 24 hours prior to the addition of the fluorggenic peroxidase 
substrate analysis with a plate reader. Fold change in the goups was calculated by 
comparing each treatment group with the vehicle control. Results are the means ± 
SE of 6 replicates.  
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The outcome of the ANOVA for the monocyte ROS trials provided for a p-value 
of 0.6705.  This statistic demonstrated no likely significance among the trials (see 
Appendix C: ANOVA Tables). Due to this probability, we failed to reject the null 
hypothesis for this experiment. This failure to reject the null hypothesis demonstrated that 
metolachlor likely had no significant effect on the function of ROS at the 24-hour time 
point in THP-1 monocytes. 
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CHAPTER 4 
 
DISCUSSION 
 
Overall, the greatest effect that metolachlor exposure had on the immature THP-1 
cells (monocytes) and mature THP-1 cells (macrophages) was on the levels of apoptosis 
within those cell populations. This is in keeping with findings from similar studies 
looking at human liver cells HepG2 (Hartnett et al 2013). In contrast, metolachlor had no 
effect on the cells ability to phagocytize or produce ROS.   
The two experiments regarding the function of apoptosis examined whether or not 
metolachlor had any measurable effect on the ability for THP-1 cells to carry out the 
process of apoptosis. As stated, apoptosis is a cellular function inherent in cells that 
allows them to undergo a controlled cellular degradation or death. This function is 
important for the maintenance of homeostasis within organisms and serves as a check on 
injured or otherwise damaged cells. If this process degraded in cells, they can continue to 
exist and impair normal function or even lead to cancer (Gerl and Vaux 2005). If the 
process of apoptosis is increased, there could be in turn, an increase in cellular death 
among what were otherwise, healthy cells. This too could impair normal, healthy 
function in an organism. Lastly, metolachlor may not have had any effect on the function 
of apoptosis in THP-1 cells. By rejecting our null hypothesis; that metolachlor would 
have no effect on the function of apoptosis, we can say that metolachlor had a probable 
effect on the function of apoptosis. Further examination into the portion of the study 
presented us with the particulars of this alteration. 
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Even though there have not been specific studies examining the clearance times 
involved in the removal of metolachlor from the body, it is likely that this process is not a 
fast one. Support can be drawn for this from the hospital study performed by Barr et al. in 
which the levels of metolachlor in umbilical cord blood samples were compared to 
human birth weights. Many of the subjects had detectable levels of metolachlor, even 
though there was no history of recent exposure to herbicides (Barr et al. 2010). This 
would imply that elevated levels of metolachlor could potentially be present in the lung 
even after a single inhalation exposure, thus it is likely the net effect would be increased 
levels of apoptosis in both alveolar macrophages and other monocytes that are present in 
the lung parenchyma. This effect, in turn could lead to a decrease in the total overall 
numbers of these cells in the lung. Various animal models of alveolar macrophage 
depletion have demonstrated multiple health effects associated with this condition. These 
effects include increased sensitization to allergens (Mathie et al. 2015), changes in 
cytokine production and inflammatory cell recruitment within the lung (Hammerbeck et 
al. 2016) and an increased susceptibility and severity of various infectious agents in the 
lung (Deady et al. 2014 and Ghoneim et al. 2013). Therefore, even moderate changes in 
apoptosis rates because of metolachlor exposure could lead to a variety of effects on 
normal lung function and overall health. 
Another finding from this current research was the different apoptosis patterns 
between metolachlor treated monocyte and macrophage populations. This may be a result 
of differences in actual functions of the two cell types. Recent work by Janssen and 
colleagues (2011), demonstrated a similar difference, with resident lung macrophages 
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having a different rate of apoptosis as compared to freshly migrated monocytes and 
macrophages during the resolution of acute lung injury (Janssen et al. 2011). In the 
present research, we did observe a slower start to apoptosis in the macrophage cell line, 
which was faster with the monocytes. It is also possible that the time to apoptosis 
observed in the macrophages was an artifact due to pre-treatment with PMA in an effort 
to stimulate their maturation. Several groups have demonstrated increased rates of cell 
apoptosis in cancer cell lines when chemotherapeutic drugs are combined with PMA or 
similar activating compounds (Seo et al. 2014). This is likely not an explanation for our 
current results, since even the monocytes, not pre-treated with PMA, also had increased 
levels of apoptosis after exposure to metolachlor. Since the apoptosis changes appear to 
be real, the next line research may look at the mechanism of change in detail.  
The two experiments regarding the function of phagocytosis examined the effects 
that metolachlor may have had on the ability of THP-1 monocytes and macrophages to 
carry out the critical function of phagocytosis. As stated earlier in this study, it was 
uncertain as to what the effects, if any, would be. The possibilities existed for an increase 
in phagocytic function, a decrease in function or no measurable effect at all. With our 
failure to reject our null hypothesis, that metolachlor will have no effect on the 
phagocytic function of THP-1 monocytes and macrophages; left us with the third 
possibility: that metolachlor had no statistically significant and measurable effect on 
phagocytosis in THP-1 cells. Several studies have demonstrated harmful effects of 
increased or decreased monocyte/macrophage phagocytic activity on lung health 
(Aderem and Underhill 1999). Since we demonstrated no changes in phagocytosis with 
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metolachlor exposure in this project it is my conclusion that metolachlor would have 
minimal effects on infection suppression or inflammation associated with alveolar 
macrophage activation in the lungs. The results from this study provide no indication that 
metolachlor exposure had any significant effect on the process of phagocytosis, given the 
exposure amounts and times used.   
We conducted the fifth and final experiment to determine the effect of 
metolachlor on the production of ROS within THP-1 monocytes during the 24-hour time-
point. Again, ROS production in THP-1 cells is important in that it allows phagocytic 
cells to weaponize and destroy foreign bodies and materials (Jisselmuiden et al. 2008). If 
this function was degraded, cells might be unable to destroy these invaders as well. If too 
much ROS is generated the ROS could subsequently damage healthy neighboring cells 
and surrounding tissues (Jisselmuiden et al 2008). The third possibility was that 
metolachlor might not have any effect at all on the production of ROS. Within the scope 
of this study, we were unable to reject the null and this failure to reject the null means 
that there was no statistically demonstrable effect of metolachlor on the production of 
ROS in THP-1 cells.  
In summary, our results indicated that metolachlor had no statistical effects on the 
functions of phagocytosis or on the production of reactive oxygen species. However, in 
regards to process of apoptosis it appears likely that metolachlor does have some impact 
on the THP-1 cells over the concentrations and time points used within the scope of this 
study. During the monocyte apoptosis study there was a probable increase in apoptosis in 
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during the 48-hour time point. Interestingly enough, the data yielded from the 
macrophage trials indicated that there was some effect in apoptotic function, though this 
influence was distinct from the monocytic trials. The 24 and 48 hour trials demonstrated 
a probable decrease in apoptosis, in Q2 (late stage apoptosis) and Q4 (apoptosis) 
respectively. This decrease is similar to results from previous experiments utilizing 
HepG2 human liver cells (Hartnett et al 2013). The 72-hour trial again demonstrated a 
likely change in function, although this change was an increase in Q2 (late stage 
apoptosis). This difference amongst the time trials is interesting in that the two shorter 
trials, 24 and 48 hour trials indicate an overall decrease in apoptotic function, and the 
longest of the time trials, the 72 hour trial indicates a higher amount of late stage 
apoptosis.  
Future Research 
Though this study did not definitively demonstrate any links between metolachlor 
and the functions of phagocytosis and the production of ROS, it did demonstrate 
statistically significant change in the function of apoptosis in THP-1 cells at three 
different time points and at various concentrations. These findings, while novel in terms 
of THP-1 cells, are similar to those in preceding studies into the effects of metolachlor on 
human cells (Hartnett et al. 2013). This linkage bares further investigation, possibly 
utilizing different concentrations or chronic exposure to metolachlor. These exposure 
variables are perhaps of greatest concern, as they could replicate the low levels of 
exposure to metolachlor a farm or field worker receives over a prolonged period. Studies 
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show that metolachlor has a persistent EPA soil classification and is listed as mobile to 
highly mobile chemical (EPA Red Facts 1995). These characteristics imply that 
metolachlor and degradates can persist in the environment and can easily transit through 
multiple natural barriers, contaminating non-target organisms and locations (Curwin et al. 
2005). Further investigation into how it affects apoptosis is appropriate, perhaps 
examining the chemical processes behind its capacity to alter apoptotic function. As 
stated earlier apoptosis is a multi-tiered process with multiple steps, any of which, when 
interfered with, could inhibit the process altogether (Wong 2011). It would be a 
worthwhile effort to examine the cell cycle step or steps that metolachlor interferes with 
and isolate the affected pathways. Previous studies have raised interesting questions 
regarding metolachlor exposed cells, specifically the HepG2 line, and the affects it may 
have on protein production. Lowry and colleagues suggested that at high levels of 
exposure (1,000 ppb) and at a 72-hour time point there was a decrease in cell numbers 
due to an altered cell cycle (Lowry et al. 2013).  
It is also possible that metolachlor will have effects on other cells within the 
human body. This study only tested two cells types, and closely related ones at that. A 
great many cell types in the body, and myriad different animal species could be affected 
by metolachlor. Several previous studies demonstrated that metolachlor could have a 
deleterious effect on non-target organisms and tissues (Barr et al. 2010). These 
potentialities present a strong argument for looking into the more critical possibilities. 
With the possibility of environmental contamination, it is incumbent upon science to 
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enrich understanding of the effects this pesticide may have on the various cells types, 
tissues and organisms and the surrounding environment in which it is used.    
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APPENDIX A 
PHAGOCYTOSIS TRIALS 
 
24 Hour Monocyte Phagocytosis 
 Trial  Metric Control 50 100 500 1K  
 
1   
Median  106 107 109 110 103 
 Mean  114 113 116 117 112 
 Percent  28.50% 25.60% 23.50% 25.30% 23.75% 
 
2  
Median  106 103 106 107 106 
 Mean  115 112 115 114 115 
 Percent  28.50% 28.14% 29.69% 26.70% 29.60% 
 
3 
Median  652 619 626 578 542 
 Mean  698 663 670 631 586 
 Percent  71.70% 42.11% 36.90% 41.56% 39.59% 
 
4  
Median  652 864 919 801 711 
 Mean  692 886 925 825 745 
 Percent  10.73% 23.86% 12.62% 28.19% 26.23% 
 
5  
Median  449 454 459 468 447 
 Mean  474 477 482 491 470 
 Percent  72.76% 56.21% 52.62 53.62 49.47 
 
6  
Median  445 506 450 405 449 
 Mean  471 526 473 431 472 
 Percent  71.67 67.84% 69.51% 72.67% 71.83% 
 
7  
Median  5188 5031 4791 4888 5082 
 Mean  5719 5531 5206 5338 5518 
 Percent  43.9 41.6 39.3 328.6 38.59 
 
8  
Median  4029 4793 4743 4614 4462 
 Mean  4443 5184 5101 4951 4796 
 Percent  40.2 36.14 37.84 38.39 39.6 
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24 Hour Monocyte Phagocytosis Normalization  
Trial  50 100 500 1K  
1 1.009434 1.018692 1.009174 0.936364 
2 0.973913 1.026786 0.991304 1.008772 
3 0.949387 1.011309 0.923323 0.937716 
4 1.325153 1.063657 0.8716 0.88764 
5 1.011136 1.011013 1.019608 0.955128 
6 1.137079 0.889328 0.9 1.108642 
7 0.969738 0.952296 1.020246 1.039689 
8 1.189625 0.989568 0.972802 0.967057 
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48 Hour Monocyte Phagocytosis  
Trial  Metric Control 50 100 500 1K  
 
1 
Median  102 98 98 99 109 
 Mean  115 112 115 116 119 
 Percent  31.87% 19.51% 21.64% 10.34% 17.83% 
 
2 
Median  96 96 103 99 100 
 Mean  112 119 115 115 117 
 Percent  23.73% 27.24% 28.42% 31.41% 28.77% 
 
3 
Median  3515 3573 3575 3644 3331 
 Mean  3714 3770 3766 3834 3548 
 Percent  74.55% 75.90% 75.90% 72.50% 76.49% 
 
4 
Median  3579 3556 3588 3436 2436 
 Mean  3766 3747 3810 3651 2660 
 Percent  77.53% 75.04% 76.63% 78.67% 72.05% 
 
5 
Median  6952 7188 7585 7618 7350 
 Mean  8551 8764 9161 9077 8909 
 Percent  28.02% 28.02% 25.08% 27.18% 26.00% 
 
6 
Median  6426 6705 6410 6394 6559 
 Mean  7552 7827 7451 7365 7683 
 Percent  26.72% 26.09% 26.50% 27.80% 26.62% 
 
7 
Median  3515 3573 3575 3644 3331 
 Mean  3714 3770 3766 3834 3548 
 Percent  74.55% 75.92% 73.49% 72.54% 76.49% 
 
8 
Median  3798 3645 3874 3615 3782 
 Mean  4584 4385 4704 4420 4551 
 Percent  21.8 27.23 13.45 22.91 18.79 
 
9  
Median  4246 4981 2788 4628 4728 
 Mean  5000 5590 3654 5349 5359 
 Percent  23.77 6.8 17.04 10.8 11.46 
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48 Hour Monocyte Phagocytosis Normalization  
Trial  50 100 500 1K  
1 0.960784 1 1.010204 1.10101 
2 1 1.072917 0.961165 1.010101 
3 1.016501 1.00056 1.019301 0.914105 
4 0.993574 1.008999 0.957637 0.708964 
5 1.033947 1.055231 1.004351 0.96482 
6 1.043417 0.956003 0.997504 1.025805 
7 1.016501 1.00056 1.019301 0.914105 
8 0.959716 1.062826 0.933144 1.046196 
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72 Hour Monocyte Phagocytosis 
Trial  Metric Control 50 100 500 1K  
 
1 
Median  106 105 103 105 112 
 Mean  114 114 113 114 120 
 Percent  22.93% 29.59% 27.14% 20.64% 25.48% 
 
2 
Median  106 106 105 109 107 
 Mean  113 115 113 115 115 
 Percent  25.56% 27.04% 21.06% 26.29% 16.26% 
 
3 
Median  2727 3374 3391 3494 3168 
 Mean  2855 3454 3465 3564 2373 
 Percent  75.80% 66.60% 64.17% 61.18% 64.89% 
 
4 
Median  3285 3418 3446 3250 2267 
 Mean  3382 3506 3510 3354 2410 
 Percent  68.97% 58.64% 56.89% 59.57% 71.60% 
 
5 
Median  614 613 595 608 621 
 Mean  632 628 616 622 644 
 Percent  50% 25.52% 44.60% 31.20% 32.62% 
 
6 
Median  695 702 738 704 727 
 Mean  704 706 737 709 728 
 Percent  34.80% 13.23% 19.45% 27.93% 22.56% 
 
7 
Median  7029 7134 7731 7311 6988 
 Mean  7797 7905 8598 8066 7667 
 Percent  35.6 31.45 30.8 31.58 33.5 
 
8 
Median  6754 7157 6769 6922 6624 
 Mean  7383 7812 7413 7515 7268 
 Percent  34.15 33.02 35.85 36.87 35.87 
 
9 
Median  4531 4632 4382 4390 4477 
 Mean  4837 4930 4690 4684 4739 
 Percent  50.6 44.66 41.06 41.3 41.52 
 
10  
Median  3428 4190 4215 4098 3850 
 Mean  3648 4458 4458 4332 4099 
 Percent  40.8 37.9 39.09 39.65 41.13 
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72 Hour Monocyte Phagocytosis Normalization  
Trial  50 100 500 1K  
1 0.990566 0.980952381 1.019417 1.066667 
2 1 0.990566038 1.038095 0.981651 
3 1.237257 1.00503853 1.030375 0.906697 
4 1.040487 1.008191925 0.943122 0.697538 
5 0.998371 0.970636215 1.021849 1.021382 
6 1.010072 1.051282051 0.95393 1.03267 
7 1.014938 1.083683768 0.945673 0.95582 
8 1.059668 0.945787341 1.022603 0.956949 
 
 
24 Hour Macrophage Phagocytosis 
Trial  Metric Control  50 100 500 1K  
1   
Median  750 722 730 663 589 
Mean  1064 1083 1049 1007 860 
Percent  63.00% 87.00% 77.00% 81.40% 78.00% 
2  
Median  876 1012 847 856 726 
Mean  1183 1379 1142 1148 1035 
Percent  89.00% 89.60% 89.76% 68.34% 88.70% 
3 
Median  5732 5529 5256 5466 5747 
Mean  7217 6827 6424 6741 7059 
Percent  86.50% 85.00% 84.00% 85.00% 83.60% 
4 
Median  4432 5337 5361 5180 5060 
Mean  5334 6426 6359 6219 6177 
Percent  85.50% 83.10% 84.75% 84.90% 86.30% 
 
24 Hour Macrophage Phagocytosis Normalization  
Trial  50 100 500 1K  
1 0.962667 1.01108 0.908219 0.888386 
2 1.155251 0.836957 1.010626 0.848131 
3 0.964585 0.950624 1.039954 1.051409 
4 1.204197 1.004497 0.966238 0.976834 
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48 Hour Macrophage Phagocytosis 
Trial  Metric Control  50 100 500 1K  
1 
Median  1952 1325 1258 1355 1104 
Mean  5427 5541 5889 5117 5266 
Percent  79.8% 75.23% 74.3% 73.3% 74.2% 
2 
Median  1878 1245 1458 1645 1358 
Mean  5406 5316 5945 4958 5847 
Percent  78.9% 72.3% 70.0% 75.2% 73.6% 
3 
Median  1755 1029 1104 1302 1245 
Mean  4656 4723 4564 4358 4987 
Percent  78.00% 72.00% 73.00% 75.00% 76.00% 
4 
Median  2349 1773 2252 1987 2179 
Mean  4985 4478 5210 4877 4762 
Percent  78.12% 70.00% 73.00% 75.00% 79.00% 
5 
Median  1808 1947 1802 1876 1838 
Mean  4747 4947 4589 4796 4759 
Percent  78.9 78.24 76.39 79.7 79.25 
 
48 Hour Macrophage Phagocytosis Normalization  
Trial  50 100 500 1K  
1 1.021006 1.062805 0.868908 1.029119 
2 0.983352 1.118322 0.833978 1.179306 
3 0.586325 1.072886 1.179348 0.956221 
4 0.754789 1.270164 0.882327 1.096628 
5 1.076881 0.925526 1.041065 0.979744 
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72 Hour Macrophage Phagocytosis 
Trial  Metric Control  50 100 500 1K  
1  
Median  690 574 636 604 605 
Mean  849 722 786 748 805 
Percent  83.70% 69.73% 82.13% 72.98% 73.93% 
2  
Median  823 555 721 779 730 
Mean  1023 741 882 954 900 
Percent  71.20% 65.30% 72.05% 76.80% 73.07% 
3   
Median  1615 1685 1731 1640 1593 
Mean  5110 5620 6214 5819 5284 
Percent  69.40% 71.00% 70.00% 71.00% 71.00% 
4 
Median  1547 1672 1920 1679 1565 
Mean  4800 4806 6430 56425 4888 
Percent  73.00% 72.40% 71.60% 71.03% 73.00% 
5 
Median  10593 9345 7526 9982 9257 
Mean  19254 17530 20921 18076 17600 
Percent  95.73 96 82 96 95.6 
 
72 Hour Macrophage Phagocytosis Normalization  
Trial  50 100 500 1K  
1 0.831884 1.108014 0.949686 1.001656 
2 0.674362 1.299099 1.080444 0.937099 
3 1.043344 1.0273 0.947429 0.971341 
4 1.080802 1.148325 0.874479 0.932102 
5 0.882186 0.80535 1.326335 0.927369 
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APPENDIX B 
APOPTOSIS TRIALS 
 
 
24 Hour Monocyte Apoptosis 
  Metric Q1 (PI) Q2 (Both) Q3 (Normal) Q4 ( Annexin) 
Control  Median  760 1322 82 945 
Percent  1.38 2.48 96.06 0.08 
Annexin  Median  480 20489 203 3358 
Percent  0.04 8.3 66.79 24.87 
P.I.  
Median  73 1246 59 811 
Percent  9.9 1.59 88.47 0.03 
Axn & P.I.  Median  664 9213 154 2022 
Percent  0.22 13.5 71.7 14.5 
50 Median  674 14900 252 2098 
Percent  0.17 16.8 59.8 23.16 
50 
Median  491 13678 172 1962 
Percent  0.85 12.88 71.5 14.76 
50 Median  399 12977 115 1979 
Percent  0.59 9.93 78.21 11.27 
50 Median  279 11358 198 2016 
Percent  1.5 10.8 69.59 18.1 
100 
Median  446 4764 143 1515 
Percent  0.49 10.78 75.98 12.75 
100 Median  542 10727 210 1898 
Percent  1.5 14.72 68.66 15.12 
100 Median  627 7443 150 1956 
Percent  1.7 11.4 78.35 8.48 
100 
Median  656 11813 198 1751 
Percent  0.9 12.4 72.63 14.07 
500 Median  567 6829 122 2036 
Percent  2.8 10.1 79.5 7.4 
500 Median  696 12954 171 1737 
Percent  0.78 17.36 68.08 13.78 
500 
Median  703 8902 149 1832 
Percent  1.1 17.2 71.2 10.3 
500 Median  404 13988 236 1793 
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Percent  1.6 25.09 56.47 16.76 
1000 
Median  375 17549 159 1785 
Percent  0.67 10.2 73.1 15.9 
1000 
Median  579 9875 142 1740 
Percent  0.6 9.23 79.95 10.16 
1000 
Median  634 16887 172 1835 
Percent  0.54 11.13 73.8 14.48 
1000 
Median  360 13266 153 1785 
Percent  0.23 9.5 76.68 13.56 
      
      
24 hours Q2 Q3 Q4 
Control 1 1 1 
50 0.91 0.99 1.104 
100 0.88 1.05 0.798 
500 1.184 0.972 0.885 
1000 0.742 1.06 0.933 
 
 
48 Hour Monocyte Apoptosis 
  Metric Q1 (PI) Q2 (Both) Q3 (Normal) Q4 ( Annexin) 
Control  Median  725 1281 70 978 
Percent  1.2 1.7 97 0.09 
Annexin  Median  609 2076 113 1365 
Percent  0.2 1.9 90.6 7.29 
P.I.  Median  191 1278 55 962 
Percent  7.8 1.17 90.9 0.02 
Axn & P.I.  Median  618 2671 164 1489 
Percent  1.2 7.06 81.48 10.25 
50 Median  292 4097 134 1742 
Percent  1.01 9.9 77.05 12 
50 Median  637 7368 198 1926 
Percent  0.9 13.3 70 15.7 
50 Median  541 3557 126 361 
Percent  5.1 10.3 77.8 6.68 
50 Median  413 3904 176 1694 
Percent  1.5 10.1 76.08 12.24 
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100 Median  371 4257 175 1660 
Percent  1.9 9.5 76.6 11.9 
100 Median  637 7368 198 1926 
Percent  0.9 13.3 70 15.9 
100 Median  541 3557 126 1679 
Percent  5.1 10.38 77.84 7.02 
100 Median  413 3904 176 1694 
Percent 1.5 10.1 76.08 12.24 
500 Median  248 4775 166 1762 
Percent  2.2 8.9 78.06 10.76 
500 Median  560 3836 189 1681 
Percent  1.4 15.6 68.43 14.5 
500 Median  306 4422 167 1623 
Percent  1.36 10.4 76.4 11.72 
500 Median  298 3764 210 1456 
Percent  2.3 13.2 66.85 12.2 
1000 
Median  431 7474 204 1862 
Percent  1.9 13.7 69 15.2 
1000 
Median  462 9285 161 2027 
Percent  1.89 16.98 69 12 
1000 
Median  527 8646 178 1792 
Percent  1.8 15.6 69.89 12.63 
1000 
Median  356 4837 166 1690 
Percent  0.85 11.7 75.65 11.76 
      
      
      48 hours  Q2 Q3 Q4 
Control 1 1 1 
50 1.5 0.927 1.14 
100 1.48 0.929 1.12 
500 1.75 0.881 1.26 
1000 2.05 0.87 1.26 
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72 Hour Monocyte Apoptosis  
  Metric Q1 (PI) Q2 (Both) Q3 (Normal) Q4 ( Annexin) 
Control  Median  1546 2658 38 1766 
Percent  0.02 0.11 99.8 0.02 
Annexin  Median  193 6420 111 3597 
Percent  0.01 0.24 92.1 7.5 
P.I.  Median  147 2017 34 0 
Percent  1.65 0.12 98.2 0 
Axn & P.I.  Median  127 1138 4939 2827 
Percent  0.24 2.4 93.5 3.93 
50 Trial 1 Median  565 10976 122 4272 
Percent  0.06 2.05 90.64 7.25 
50 Trial 2 Median  914 8974 99 4108 
Percent  0.1 3.3 89.9 6.68 
50 Trial 3 Median  1044 10733 126 3941 
Percent  0.11 3.3 89.4 7.17 
50 Trial 4 Median  652 6877 76 3255 
Percent  0.14 2.7 86.6 10.5 
100 Trial 1 Median  888 7328 150 3617 
Percent  0.02 2.7 91.4 5.86 
100 Trial 2 Median  583 6961 139 4280 
Percent  0.07 2.55 89.45 7.93 
100 Trial 3 Median  1003 6284 87 3150 
Percent  0.19 3.09 91.2 5.5 
100 Trial 4 Median  853 8453 107 5021 
Percent  0.05 2.36 90.59 7 
500 Trial 1 Median  844 5387 125 4789 
Percent  0.05 4.8 88.37 6.77 
500 Trial 2 Median  614 5833 138 2815 
Percent  0.1 3 88.7 8.16 
500 Trial 3 Median  785 6964 131 3152 
Percent  0.09 2.7 91.18 6.02 
500 Trial 4 Median  567 5013 113 2721 
Percent  0.27 2.85 85.79 11.09 
1000 Trial 1 
Median  1075 5055 134 2589 
Percent  0.36 3.72 88.61 7.3 
1000 Trial 2 Median  1058 8217 185 3244 
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Percent  0.04 2.8 89.68 7.47 
1000 Trial 3 
Median  680 7431 117 3060 
Percent  0.17 2.88 90.12 6.83 
1000 Trial 4 
Median  629 5161 125 2764 
Percent  0.26 2.7 87.1 9.92 
      
      72 hours  Q2 Q3 Q4 
  Control 1 1 1 
  50 1.181 1.064 1.91 
  100 1.292 0.965 1.682 
  500 1.423 0.947 2.002 
  1000 1.261 0.951 2.005 
   
24 Hour Macrophage Apoptosis 
  Metric Q1 (PI) Q2 (Both) Q3 (Normal) Q4 ( Annexin) 
Control  Median  0 1938 138 905 
Percent  0 3.7 92.1 4.1 
Annexin  Median  0 2085 63 507 
Percent  0 6.17 63.2 30.6 
P.I.  Median  1134 4961 309 3728 
Percent  12.2 6.69 80.07 1.04 
Axn & P.I.  Median  2340 26276 687 8693 
Percent  0.27 20.48 60.38 18.87 
50 Trial 1 Median  2141 29456 658 9915 
Percent  0.39 18.6 63.9 19.03 
50 Trial 2 Median  1867 20769 483 9875 
Percent  1.3 21.05 59.34 18.31 
50 Trial 3 Median  2198 20914 409 9968 
Percent  0.63 20.32 59.36 19.69 
50 Trial 4 Median  2059 23992 554 10026 
Percent  0.74 18.7 64.1 16.93 
50 Trial 5 Median  2050 25981 571 9164 
Percent  0.51 20.99 58.8 19.64 
100 Trial 1 Median  2452 18442 540 7753 
Percent  0.51 20.35 64.5 14.64 
100 Trial 2 Median  2304 22462 599 8000 
Percent  0.44 17.35 66.75 15.46 
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100 Trial 3 Median  2048 28844 625 7750 
Percent  0.29 15.78 69.53 14.4 
100 Trial 4 Median  2262 22068 574 8283 
Percent  0.45 18.9 65.33 15.32 
100 Trial 5 Median  1999 29846 639 7681 
Percent  0.32 18.55 62.49 18.64 
500 Trial 1 Median  1978 20867 501 8549 
Percent  0.36 18.7 64.2 16.67 
500 Trial 2 Median  2143 18427 715 7524 
Percent  0.57 21.49 57.61 20.33 
500 Trial 3 Median  2161 13723 533 6238 
Percent  0.99 20.2 62.9 15.87 
500 Trial 4 Median  2521 20903 589 9462 
Percent  0.18 17.35 66.6 15.86 
500 Trial 5 Median  2249 20550 683 12322 
Percent  0.11 27.89 44.86 27.14 
1000 Trial 1 
Median  2254 21170 648 7244 
Percent  0.42 14.8 69.8 14.9 
1000 Trial 2 
Median  2118 13833 539 6965 
Percent  1.27 16.35 69.39 12.9 
1000 Trial 3 
Median  2036 23224 518 9816 
Percent  0.51 19.67 61.43 18.39 
1000 Trial 4 
Median  2155 27079 778 6841 
Percent  0.27 16.8 63.35 19.52 
1000 Trial 5 
Median  2738 25976 564 9063 
Percent  0.37 17.3 67.39 14.93 
      
      24 hours  Q2 Q3 Q4 
  Control 1 1 1 
  50 0.973 1.012 0.992 
  100 0.888 1.088 0.832 
  500 1.032 0.981 1.016 
  1000 0.829 1.104 0.855 
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48 Hour Macrophage Apoptosis 
  Metric Q1 (PI) Q2 (Both) Q3 (Normal) Q4 ( Annexin) 
Control  Median  1014 1477 103 1206 
Percent  0.15 0.96 98.6 0.2 
Annexin  Median  1015 1997 181 1327 
Percent  0.01 1.09 94.5 4.4 
P.I.  Median  232 1396 120 1151 
Percent  6.9 1.06 91.94 0.02 
Axn & P.I.  Median  803 3159 153 1933 
Percent  0.44 9.09 56.85 33.62 
50 Trial 1 Median  497 7684 212 3244 
Percent  0.12 6.4 69.9 12.2 
50 Trial 2 Median  718 5202 120 2843 
Percent  0.56 18.8 41.2 39.4 
50 Trial 3 Median  418 5806 198 2889 
Percent  0.26 6.8 63.9 28.9 
50 Trial 4 Median  824 1921 198 1485 
Percent  1.7 8.8 68.6 20.78 
50 Trial 5 Median  803 3046 172 1925 
Percent  0.62 9.98 67.1 22.2 
100 Trial 1 Median  636 1151 159 4212 
Percent  0.23 10.8 29.8 59.1 
100 Trial 2 Median  820 1846 200 1385 
Percent  2.4 7.8 79.3 10.42 
100 Trial 3 Median  681 3380 171 1939 
Percent  0.32 8.4 68.3 22.83 
100 Trial 4 Median  900 3458 171 1974 
Percent  0.01 7.05 71.2 20.74 
100 Trial 5 Median  329 1517 316 2015 
Percent  0.35 8.05 63.9 31 
500 Trial 1 Median  806 2392 478 1776 
Percent  3.7 28.43 34.43 33.38 
500 Trial 2 Median  607 4000 186 2225 
Percent  0.13 6.48 62.71 30.68 
500 Trial 3 Median  734 1642 144 1264 
Percent  4.2 3.7 89.4 2.6 
500 Trial 4 Median  378 1446 186 1247 
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Percent  10.6 2.12 87.3 0.5 
500 Trial 5 Median  156 1391 110 1127 
Percent  6.01 1 92.8 0.19 
1000 Trial 1 
Median  322 1516 120 1140 
Percent  5.8 1.5 92.45 0.22 
1000 Trial 2 
Median  667 2755 176 1703 
Percent  0.88 5.49 79.86 13.77 
1000 Trial 3 
Median  540 1618 115 1239 
Percent  5 2.39 91.85 0.76 
1000 Trial 4 
Median  216 1545 97 1146 
Percent  4.5 1.18 94.2 0.08 
1000 Trial 5 
Median  687 1611 180 1357 
Percent  4.27 3.06 89.15 3.5 
      
      48 hours  Q2 Q3 Q4 
  Control 1 1 1 
  50 1.117 1.093 0.735 
  100 0.684 1.113 0.875 
  500 0.918 1.291 0.4 
  1000 0.3 1.574 0.11 
   
 
72 Hour Macrophage Apoptosis 
  Metric Q1 (PI) Q2 (Both) Q3 (Normal) Q4 ( Annexin) 
Control  Median  1014 1477 103 1206 
Percent  0.15 0.96 98.6 0.2 
Annexin  Median  247 2225 75 1607 
Percent  0.1 0.29 99.35 0.26 
P.I.  Median  225 1859 71 1422 
Percent  3.06 0.59 96.3 0.01 
Axn & P.I.  Median  259 1976 85 1533 
Percent  4.12 0.58 95.25 0.5 
50 Trial 1 Median  138 1886 75 2518 
Percent  7.43 0.65 91.8 0.04 
50 Trial 2 Median  224 1928 70 2087 
Percent  6.5 0.64 92.5 0.24 
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50 Trial 3 Median  195 1939 85 2097 
Percent  8.65 0.69 90.51 0.15 
50 Trial 4 Median  288 2063 74 1707 
Percent  3.5 0.72 95.51 0.25 
50 Trial 5 Median  383 2102 94 1788 
Percent  8.3 2.06 89.36 0.28 
100 Trial 1 Median  335 1717 112 2456 
Percent  6.25 1.07 92.48 0.2 
100 Trial 2 Median  525 1938 106 1864 
Percent  6.27 1.53 91.92 0.28 
100 Trial 3 Median  533 1956 130 1668 
Percent  10.17 1.86 87.54 0.43 
100 Trial 4 Median  739 2086 98 1841 
Percent  4.66 2.35 91.5 1.49 
100 Trial 5 Median  584 2062 132 1670 
Percent  4.16 2 92.38 1.46 
500 Trial 1 Median  1236 1961 97 1652 
Percent  0.14 0.62 99.08 0.16 
500 Trial 2 Median  329 1771 93 1604 
Percent  7.9 1.06 90.9 0.03 
500 Trial 3 Median  331 1854 80 2824 
Percent  5.58 0.8 93.47 0.15 
500 Trial 4 Median  361 1806 96 845 
Percent  14.68 0.94 84.2 0.12 
500 Trial 5 Median  282 2077 87 1694 
Percent  4.47 0.83 94.63 0.07 
1000 Trial 1 
Median  227 1733 83 1518 
Percent  7.8 0.5 91.66 0.02 
1000 Trial 2 
Median  250 1883 75 1003 
Percent  6.36 0.78 92.86 1.4 
1000 Trial 3 
Median  287 1819 117 1608 
Percent  11.56 1.07 87.32 0.05 
1000 Trial 4 
Median  246 1906 85 1505 
Percent  3.8 0.73 95.39 0.06 
1000 Trial 5 
Median  370 1905 102 3310 
Percent  9.56 0.71 89.58 0.15 
      
 
     
75 
 
 
 
72 hours  Q2 Q3 Q4 
  Control 1 1 1 
  50 1.64 0.965 0.384 
  100 3.03 0.957 1.544 
  500 1.465 0.971 0.212 
  1000 1.307 0.959 0.672 
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APPENDIX C 
REACTIVE OXYGEN SPECIES 
 
24 Hour Reactive Oxygen Species 
Trial 1 Control 50 100 500 1,000 
A 2587 3004 1613 1613 1703 
B 2500 2793 1490 1888 1976 
C 2638 2749 1754 1619 1235 
D 2507 2867 1630 1801 1887 
Average 2558 2853.25 1621.75 1730.25 1700.25 
Trial 2 Control 50 100 500 1,000 
A 7692 7771 3913 7030 6775 
B 7464 8346 5659 8752 8166 
C 7817 7460 5452 6684 3904 
D 7830 9219 4825 5312 8878 
Average 7700.75 8199 4962.25 6944.5 6930.75 
Trial 3 Control 50 100 500 1,000 
A 19798 17317 17412 19497 19432 
B 17759 17855 16128 16998 15867 
C 17760 16064 12932 15829 16586 
D 19508 17688 18343 13894 14237 
Average 18706.25 17231 16203.75 16554.5 16530.5 
Trial 4 Control 50 100 500 1,000 
A 40336 32345 23401 42042 41773 
B 35401 33527 31446 22349 37301 
C 35758 29014 25149 38214 30985 
D 36555 30679 23512 25060 35576 
Average 37012.5 31391.25 25877 31916.25 36408.75 
Trial 5 Control 50 100 500 1,000 
A 45720 57205 22277 71550 68680 
B 58914 51368 53040 20051 10571 
C 39586 45729 42595 41009 27710 
D 49087 47759 21094 36945 27724 
Average 48326.75 50515.25 34751.5 42388.75 33671.25 
Trial 6 Control 50 100 500 1,000 
A 44290 40984 32229 Overflow Overflow 
B 37497 53470 49159 30981 45140 
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C 37238 65760 66100 45227 26249 
D 56625 67479 31016 39337 30438 
Average 43912.5 56923.25 44626 38515 33942.33 
 
24 Hour ROS Normalized  
Trial # Control 50 100 500 1000 
1 1 1.115422 0.633991 0.676407 0.664679 
2 1 1.064701 0.644385 0.901795 0.90001 
3 1 0.921136 0.866221 0.884972 0.883689 
4 1 0.848126 0.699142 0.86231 0.983688 
5 1 1.045285 0.719094 0.877128 0.696741 
6 1 1.296288 1.016248 0.877085 0.772954 
Graph  1 1.048493 0.76318 0.846616 0.81696 
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APPENDIX D 
ANOVA TABLES 
 
ANOVA: Single Factor  
Monocyte Phagocytosis  
α=0.05 
     
       SUMMARY 
      Groups Count Sum Average Variance 
  
Row 1 5 5.01 1.002 
0.00168
6 
  
Row 2 5 4.972 0.9944 
0.00047
9 
  
Row 3 5 4.997742127 
0.99954
8 
0.00105
5 
  
       
       ANOVA 
      Source of 
Variation SS Df MS F P-value F crit 
Between Groups 0.00015 2 
7.52E-
05 
0.07008
5 
0.93269
3 
3.88529
4 
Within Groups 
0.01288
1 12 
0.00107
3 
   
       
Total 
0.01303
1 14         
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ANOVA: Single Factor 
      Macrophage Phagocytosis  
α=0.05 
      SUMMARY 
      Groups Count Sum Average Variance 
  
Row 1 5 4.945 0.989 
0.00270
6 
  
Row 2 5 4.983 0.9966 
0.00633
1 
  
Row 3 5 4.971 0.9942 
0.00468
4 
  
       
       ANOVA 
      Source of Variation SS Df MS F P-value F crit 
Between Groups 
0.00015
1 2 7.55E-05 
0.01650
1 
0.98365
7 
3.88529
4 
Within Groups 
0.05488
2 12 
0.00457
4 
   
       
Total 
0.05503
3 14         
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ANOVA: Single Factor 
    MonocyteApoptosis 
Q2: 24 hours 
α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 4 4 1 0 
  Column 2 4 3.6896 0.922407 0.051256104 
  Column 3 4 3.6519 0.912963 0.01643219 
  Column 4 4 4.4259 1.106481 0.062939323 
  Column 5 4 2.9674 0.741852 0.003948605 
  
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 0.286265 4 0.071566 2.658945148 0.073849312 3.055568 
Within Groups 0.403729 15 0.026915 
   
       Total 0.689993 19         
       
ANOVA: Single Factor 
    MonocyteApoptosis 
Q2: 48 hours  
α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 4 4 1 0 
  Column 2 4 6.175637 1.543909 0.051896 
  Column 3 4 6.130312 1.532578 0.057545 
  Column 4 4 6.813031 1.703258 0.177672 
  Column 5 4 8.201133 2.050283 0.103306 
  
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 2.301324 4 0.575331 7.368106 0.001722 3.055568 
Within Groups 1.17126 15 0.078084 
   
       Total 3.472584 19         
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ANOVA: Single Factor 
MonocyteApoptosis 
Q2: 72 hours 
    α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 4 4 1 0 
  Column 2 4 4.729167 1.182292 0.06174 
  Column 3 4 4.458333 1.114583 0.016649 
  Column 4 4 5.5625 1.390625 0.167643 
  Column 5 4 5.041667 1.260417 0.038212 
  
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 0.34822 4 0.087055 1.531341 0.243416 3.055568 
Within Groups 0.852734 15 0.056849 
   
       Total 1.200955 19         
 
ANOVA: Single Factor 
MonocyteApoptosis 
Q4: 24 hours  
    α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Row 1 5 73.71 14.742 32.53382 
  Row 2 5 68.32 13.664 4.07788 
  Row 3 5 59.03 11.806 7.00638 
  Row 4 5 76.99 15.398 3.77602 
  
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 36.96738 3 12.32246 1.039999 0.401623 3.238872 
Within Groups 189.5764 16 11.84853 
   
       Total 226.5438 19         
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ANOVA: Single Factor 
MonocyteApoptosis 
Q4: 72 hours 
    α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Row 1 5 31.11 6.222 1.97587 
  Row 2 5 34.17 6.834 2.95523 
  Row 3 5 29.45 5.89 1.63315 
  Row 4 5 42.44 8.488 8.96467 
  
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 19.99498 3 6.664992 1.716795 0.203723 3.238872 
Within Groups 62.11568 16 3.88223 
   
       Total 82.11066 19         
ANOVA: Single Factor 
    
ANOVA: Single Factor 
MonocyteApoptosis 
Q4:48 hours 
    α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Row 1 5 60.11 12.022 3.71192 
  Row 2 5 68.45 13.69 6.1805 
  Row 3 5 48.3 9.66 7.31565 
  Row 4 5 58.69 11.738 0.73302 
  
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 41.01402 3 13.67134 3.048051 0.059004 3.238872 
Within Groups 71.76436 16 4.485273 
   
       Total 112.7784 19         
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MacrophageApoptosis 
Q2: 24 hours 
α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 5 102.4 20.48 0 
  Column 2 5 99.66 19.932 1.45297 
  Column 3 5 90.93 18.186 2.95323 
  Column 4 5 105.63 21.126 16.72133 
  Column 5 5 84.92 16.984 3.13003 
  
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 58.6115 4 14.65287 3.02027 0.042262 2.866081 
Within Groups 97.03024 20 4.851512 
   
       Total 155.6417 24         
 
 
ANOVA: Single Factor 
MacrophageApoptosis 
Q2: 48 hours 
    
 
 α=0.05 
    
  
SUMMARY 
     Groups Count Sum Average Variance 
 
 
Column 1 5 45.45 9.09 0 
  Column 2 5 50.78 10.156 25.48968 
  Column 3 5 42.1 8.42 2.01575 
  Column 4 5 41.73 8.346 130.2903 
  Column 5 5 13.62 2.724 2.93933 
  
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 168.2459 4 42.06149 1.308411 0.300756 2.866081 
Within Groups 642.9402 20 32.14701 
   
       Total 811.1861 24         
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ANOVA: Single Factor 
    MacrophageApoptosis 
Q4: 24 hours 
α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 5 94.35 18.87 0 
  Column 2 5 93.6 18.72 1.3139 
  Column 3 5 78.46 15.692 2.91472 
  Column 4 5 95.87 19.174 23.24063 
  Column 5 5 80.64 16.128 7.49637 
  
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Between Groups 55.41906 4 13.85477 1.981198 0.1363 2.866081 
Within Groups 139.8625 20 6.993124 
   
       Total 195.2815 24         
 
ANOVA: Single Factor 
MacrophageApoptosis 
Q2: 72 hours 
    α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 5 2.9 0.58 0 
  Column 2 5 4.76 0.952 0.38467 
  Column 3 5 8.81 1.762 0.23617 
  Column 4 5 4.25 0.85 0.027 
  Column 5 5 3.79 0.758 0.04187 
  
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 4.192456 4 1.048114 7.598222 0.000682 2.866081 
Within Groups 2.75884 20 0.137942 
   
       Total 6.951296 24         
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ANOVA: Single Factor 
MacrophageApoptosis 
Q4: 48 hours 
    α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 5 168.1 33.62 0 
  Column 2 5 123.48 24.696 102.8991 
  Column 3 5 147.09 29.418 330.0223 
  Column 4 5 67.35 13.47 288.8321 
  Column 5 5 18.33 3.666 33.82438 
  
       ANOVA 
      Source of 
Variation SS df MS F 
  Between Groups 3004.763 4 751.1908 4.970969 P-value F crit 
Within Groups 3022.312 20 151.1156 
 
0.006018 2.866081 
       Total 6027.075 24     
   
ANOVA: Single Factor 
MacrophageApoptosis 
Q4: 72 hours 
    α=0.05 
      SUMMARY 
     Groups Count Sum Average Variance 
  Column 1 5 2.5 0.5 0 
  Column 2 5 0.96 0.192 0.00957 
  Column 3 5 3.86 0.772 0.41877 
  Column 4 5 0.53 0.106 0.00303 
  Column 5 5 1.68 0.336 0.35613 
  
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 1.402064 4 0.350516 2.225498 0.102728 2.866081 
Within Groups 3.15 20 0.1575 
   
       Total 4.552064 24         
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ANOVA: Single Factor.  
α= .05 
ROS 24hrs.   
    
       SUMMARY 
     Groups Count Sum Average Variance 
  Row 1 5 4.0905 0.8181 0.04975 
  Row 2 5 4.510892 0.902178 0.025611 
  Row 3 5 4.556017 0.911203 0.002863 
  Row 4 5 4.393266 0.878653 0.014795 
  Row 5 5 4.33825 0.86765 0.02511 
  Row 6 5 4.962575 0.992515 0.038607 
  
       
       ANOVA 
      Source of 
Variation SS df MS F P-value F crit 
Between Groups 0.08376 5 0.016752 0.641286 0.670503 2.620654 
Within Groups 0.626944 24 0.026123 
   
       Total 0.710705 29         
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APPENDIX E  
TUKEY POST-HOC ANALYSIS TABLES 
 
Q2 48 Hour Apo Tukey HSD Tukey HSD Tukey HSD 
Mono Pair Q statistic p-value Inference 
A vs B 3.8929 0.0921669 insignificant 
A vs C 3.8118 0.1020816 insignificant 
A vs D 5.0334 0.0204541 * p<0.05 
A vs E 7.5172 0.0010053 ** p<0.01 
B vs C 0.0811 0.8999947 insignificant 
B vs D 1.1405 0.8999947 insignificant 
B vs E 3.6243 0.1283004 insignificant 
C vs D 1.2216 0.8999947 insignificant 
C vs E 3.7054 0.1165247 insignificant 
D vs E 2.4838 0.4336103 insignificant 
 
 
Q2 24 Hour Apo Tukey HSD Tukey HSD Tukey HSD 
Macro Pair Q statistic p-value Inference 
A vs B 0.5563 0.8999947 insignificant 
A vs C 2.3288 0.4871785 insignificant 
A vs D 0.6558 0.8999947 insignificant 
A vs E 3.5491 0.1279683 insignificant 
B vs C 1.7725 0.6996399 insignificant 
B vs D 1.2121 0.8999947 insignificant 
B vs E 2.9928 0.2519954 insignificant 
C vs D 2.9847 0.2543175 insignificant 
C vs E 1.2203 0.8999947 insignificant 
D vs E 4.2049 0.052017 insignificant 
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Q2 72 Hour Apo Tukey HSD Tukey HSD Tukey HSD 
Macro Pair Q statistic p-value Inference 
A vs B 2.2396 0.5215292 insignificant 
A vs C 7.1163 0.0010053 ** p<0.01 
A vs D 1.6256 0.7556739 insignificant 
A vs E 1.0717 0.8999947 insignificant 
B vs C 4.8767 0.0190953 * p<0.05 
B vs D 0.6141 0.8999947 insignificant 
B vs E 1.168 0.8999947 insignificant 
C vs D 5.4907 0.0073348 ** p<0.01 
C vs E 6.0446 0.0030417 ** p<0.01 
D vs E 0.5539 0.8999947 insignificant 
 
 
 
Q4 48 Hour Apo Tukey HSD Tukey HSD Tukey HSD 
Macro Pair Q statistic p-value Inference 
A vs B 1.6233 0.7565466 insignificant 
A vs C 0.7643 0.8999947 insignificant 
A vs D 3.6653 0.1100938 insignificant 
A vs E 5.4486 0.0078373 ** p<0.01 
B vs C 0.8589 0.8999947 insignificant 
B vs D 2.042 0.5968903 insignificant 
B vs E 3.8253 0.0885685 insignificant 
C vs D 2.9009 0.2790993 insignificant 
C vs E 4.6843 0.0255892 * p<0.05 
D vs E 1.7833 0.6955134 insignificant 
 
 
